Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)

INTRODUCTION: Evidence from a number of open-label, uncontrolled studies has suggested that rituximab may benefit patients with autoimmune diseases who are refractory to standard-of-care. The objective of this study was to evaluate the safety and clinical outcomes of rituximab in several standard-of...

Descripción completa

Detalles Bibliográficos
Autores principales: Tony, Hans-Peter, Burmester, Gerd, Schulze-Koops, Hendrik, Grunke, Mathias, Henes, Joerg, Kötter, Ina, Haas, Judith, Unger, Leonore, Lovric, Svjetlana, Haubitz, Marion, Fischer-Betz, Rebecca, Chehab, Gamal, Rubbert-Roth, Andrea, Specker, Christof, Weinerth, Jutta, Holle, Julia, Müller-Ladner, Ulf, König, Ramona, Fiehn, Christoph, Burgwinkel, Philip, Budde, Klemens, Sörensen, Helmut, Meurer, Michael, Aringer, Martin, Kieseier, Bernd, Erfurt-Berge, Cornelia, Sticherling, Michael, Veelken, Roland, Ziemann, Ulf, Strutz, Frank, von Wussow, Praxis, Meier, Florian MP, Hunzelmann, Nico, Schmidt, Enno, Bergner, Raoul, Schwarting, Andreas, Eming, Rüdiger, Hertl, Michael, Stadler, Rudolf, Schwarz-Eywill, Michael, Wassenberg, Siegfried, Fleck, Martin, Metzler, Claudia, Zettl, Uwe, Westphal, Jens, Heitmann, Stefan, Herzog, Anna L, Wiendl, Heinz, Jakob, Waltraud, Schmidt, Elvira, Freivogel, Klaus, Dörner, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3218885/
https://www.ncbi.nlm.nih.gov/pubmed/21569519
http://dx.doi.org/10.1186/ar3337

Ejemplares similares

Ejemplares similares